CTMX CytomX Therapeutics (CTMX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001501989
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
116
13F, latest reported quarter
What the filings say about CTMX
Insiders, 180 days
-$5.0K net sold
1 seller · 0% of sales under a 10b5-1 plan
CytomX Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CytomX Therapeutics, Inc. insiders sold a net $5.0K of stock across 48 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 17, 2026.
- The trade is 0.5% of the 295,324 shares held after it.
- No other insider sold within 30 days.
- 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Ogden Christopher sold about $5.0K of CTMX on Jun 15, 2026; 116 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 18, 2025.
- The trade is 11.2% of the 189,446 shares held after it.
- 3 other insiders sold within 30 days.
- 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Chu Yu-Waye sold about $136.6K of CTMX on Mar 17, 2026; 3 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Nov 6, 2025.
- The trade is 11.0% of the 1,078,922 shares held after it.
- 3 other insiders sold within 30 days.
- 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO McCarthy Sean A. sold about $763.8K of CTMX on Mar 17, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 16, 2025.
- The trade is 10.5% of the 300,760 shares held after it.
- 3 other insiders sold within 30 days.
- 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Scientific Officer BELVIN MARCIA sold about $202.2K of CTMX on Mar 17, 2026; 3 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 16, 2025.
- The trade is 6.5% of the 296,948 shares held after it.
- 3 other insiders sold within 30 days.
- 116 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Ogden Christopher sold about $124.1K of CTMX on Mar 17, 2026; 3 other insiders sold within 30 days and 116 funds added in the latest 13F quarter.48 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$5.0K over 180 days
more than 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
116 funds bought in last quarter
more than 74% of Pharma & Biotech
Revenue
-44.8% year over year
below 78% of Pharma & Biotech
Margin
-22.8% net margin
more than 57% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.7% of the float short (float per yahoo 2026-10-26) · 8.7 days to cover · settled 2026-09-30
more than 92% of Pharma & Biotech
What changed in the last 30 days
Oct 16CEO McCarthy Sean A. sold $461.9K under a 10b5-1 plan (Nov 6, 2025)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch CTMX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.6%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CTMX: institutional holders (13F)
13F holdings, latest reported quarter
32,714,937 sh
$122.7M
21,703,093 sh
$81.4M
17,559,822 sh
$65.8M
15,082,617 sh
$56.6M
11,747,236 sh
$44.1M
Congress trades in CTMX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CTMX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CTMX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Disruptive Medicine ETF
$403.4K position · as of 2026-05-31
1.0%
First Trust Dow Jones Select MicroCap Index Fund
$2.2M position · as of 2026-06-30
0.8%
Virtus Biotech Clinical Trials Etf
$320.1K position · as of 2026-07-31
0.7%
iShares Genomics Immunology and Healthcare ETF
$1.2M position · as of 2026-07-31
0.6%
Tema Oncology ETF
$824.4K position · as of 2026-05-31
0.5%
Fidelity Advisor Biotechnology Fund
$7.7M position · as of 2026-07-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
2 active
2
Phase 2
0 active
3
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $5.0K sold by insiders over 180 days, 116 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CTMX financials
Revenue growth
-44.8%
XBRL, annual
Net margin
-22.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$18.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CTMX
| FY Dec 2025 | $76.2M |
| FY Dec 2024 | $138.1M |
| FY Dec 2023 | $101.2M |
| FY Dec 2022 | $53.2M |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.4M |
| Mar 2026 | $10.3M |
| Dec 2025 | $663.0K |
| Sep 2025 | $6.0M |
| Jun 2025 | $18.7M |
| Mar 2025 | $50.9M |
| Dec 2024 | $38.1M |
| Sep 2024 | $33.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-435.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CTMX
| FY Dec 2025 | -22.8% |
| FY Dec 2024 | +23.1% |
| FY Dec 2023 | -0.6% |
| FY Dec 2022 | -186.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | -1,457% |
| Mar 2026 | -177.9% |
| Dec 2025 | -3,998% |
| Sep 2025 | -238.6% |
| Jun 2025 | -0.8% |
| Mar 2025 | +46.2% |
| Dec 2024 | +49.6% |
| Sep 2024 | +17.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$82.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CTMX
| FY Dec 2025 | -$75.8M |
| FY Dec 2024 | -$86.5M |
| FY Dec 2023 | -$56.9M |
| FY Dec 2022 | -$112.5M |
| FY Dec 2021 | -$120.6M |
| Jun 2026 | -$18.1M |
| Mar 2026 | -$25.5M |
| Dec 2025 | -$23.4M |
| Sep 2025 | -$15.4M |
| Jun 2025 | -$15.8M |
| Mar 2025 | -$21.2M |
| Dec 2024 | -$20.0M |
| Sep 2024 | -$20.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity CTMX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt CTMX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-37.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CTMX
| FY Dec 2025 | -35.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -37.8% |
| Mar 2026 | -34.3% |
| Dec 2025 | -35.2% |
| Sep 2025 | +66.8% |
| Jun 2025 | +108.2% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-28.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CTMX
| FY Dec 2025 | -12.8% |
| FY Dec 2024 | +19.8% |
| FY Dec 2023 | -0.2% |
| FY Dec 2022 | -33.1% |
| FY Dec 2021 | -33.2% |
| Jun 2026 | -28.6% |
| Mar 2026 | -25.8% |
| Dec 2025 | -12.8% |
| Sep 2025 | +18.9% |
| Jun 2025 | +28.7% |
| Mar 2025 | +29.4% |
| Dec 2024 | +19.8% |
| Sep 2024 | +7.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CTMX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-36.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CTMX
| FY Dec 2025 | -32.0% |
| FY Dec 2024 | +62.0% |
| FY Dec 2023 | -8.4% |
| FY Dec 2022 | -54.8% |
| FY Dec 2021 | -42.0% |
| Jun 2026 | -36.5% |
| Mar 2026 | -34.6% |
| Dec 2025 | -32.0% |
| Sep 2025 | +33.9% |
| Jun 2025 | +56.7% |
| Mar 2025 | +81.3% |
| Dec 2024 | +62.0% |
| Sep 2024 | +14.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing CTMX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value CTMX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-16.3%
TTM free cash flow over market value at close 2026-10-23
FCF yield CTMX
| FY Dec 2025 | -10.5% |
| FY Dec 2024 | -107.4% |
| FY Dec 2023 | -54.8% |
| FY Dec 2022 | -106.4% |
| FY Dec 2021 | -42.7% |
| Jun 2026 | -10.1% |
| Mar 2026 | -10.0% |
| Dec 2025 | -10.5% |
| Sep 2025 | -13.8% |
| Jun 2025 | -42.4% |
| Mar 2025 | -160.1% |
| Dec 2024 | -107.4% |
| Sep 2024 | -96.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing CTMX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $76.2M | $138.1M | $101.2M | $53.2M |
| Operating income | -$22.4M | $25.0M | -$6.5M | -$101.3M |
| Net income | -$17.4M | $31.9M | -$569.0K | -$99.3M |
| Operating cash flow | -$75.6M | -$86.2M | -$56.0M | -$110.8M |
| Cash | $12.7M | $38.1M | $17.2M | $193.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
CTMX Stock Sonar score 5/7 axes
Find similar shapesCompareCTMX ranks highest on institutional and government (74th percentile) and profitability (63rd), and lowest on growth (22nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CTMX filings, in plain words
Are CytomX Therapeutics insiders buying or selling CTMX?
In the 180 days to 2026-10-27, CytomX Therapeutics insiders were net sellers, a net $5.0K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-27, CytomX Therapeutics insiders were net sellers of CTMX, a net $5.0K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
